Thomas J. Riga Sells 2,388 Shares of Spectrum Pharmaceuticals, Inc. (SPPI) Stock
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) COO Thomas J. Riga sold 2,388 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $8.82, for a total transaction of $21,062.16. Following the completion of the transaction, the chief operating officer now owns 258,035 shares in the company, valued at $2,275,868.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of SPPI stock opened at $8.78 on Wednesday. The firm has a market cap of $966.24 million, a PE ratio of -8.69 and a beta of 2.58. Spectrum Pharmaceuticals, Inc. has a one year low of $6.22 and a one year high of $25.29.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). Spectrum Pharmaceuticals had a negative net margin of 109.76% and a negative return on equity of 37.72%. During the same quarter in the prior year, the company earned ($0.15) EPS. On average, analysts anticipate that Spectrum Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Exane Derivatives bought a new stake in shares of Spectrum Pharmaceuticals during the 4th quarter valued at $26,000. Oregon Public Employees Retirement Fund bought a new stake in shares of Spectrum Pharmaceuticals during the 4th quarter valued at $39,000. First Mercantile Trust Co. raised its position in shares of Spectrum Pharmaceuticals by 69.1% during the 4th quarter. First Mercantile Trust Co. now owns 4,795 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 1,960 shares during the period. LS Investment Advisors LLC raised its position in shares of Spectrum Pharmaceuticals by 100.6% during the 4th quarter. LS Investment Advisors LLC now owns 6,460 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 3,239 shares during the period. Finally, Quantamental Technologies LLC raised its position in shares of Spectrum Pharmaceuticals by 243.9% during the 1st quarter. Quantamental Technologies LLC now owns 7,806 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 5,536 shares during the period. Hedge funds and other institutional investors own 77.50% of the company’s stock.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
Featured Article: Is a Roth IRA right for you?
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.